Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ONCO-ADHER: Adherence to Treatment With Aromatase Inhibitors With or Without Abemaciclib in Patients With Early-stage, Endocrine-dependent, HER2-negative Breast Cancer

NCT06650423 is registered in ClinicalTrials.gov with Institute of Oncology Ljubljana as lead sponsor.

NCT NCT06650423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06650423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ONCO-ADHER: Adherence to Treatment With Aromatase Inhibitors With or Without Abemaciclib in Patients With Early-stage, Endocrine-dependent, HER2-negative Breast Cancer
Lead sponsor
Institute of Oncology Ljubljana
Phase
Observational
Overall status
Recruiting
Start date
January 5, 2025
Completion date
March 1, 2027
Enrollment
319 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

early breast cancer, her2-negative breast cancer, hormone receptor positive tumor